Safety and Tolerability of Quetiapine in Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Extended-release quetiapine fumarate

Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg

Trial Locations (1)

T2N 2T9

MS Clinic, Foothills Medical Centre, Calgary

All Listed Sponsors
collaborator

Multiple Sclerosis Society of Canada

OTHER

lead

University of Calgary

OTHER

NCT02087631 - Safety and Tolerability of Quetiapine in Multiple Sclerosis | Biotech Hunter | Biotech Hunter